Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Core Insights - BioMarin Pharmaceutical Inc reported weaker-than-expected earnings for Q3, with earnings of 12 cents per share, missing the analyst consensus estimate of 37 cents per share [1] - Quarterly sales were reported at $776.133 million, also missing the analyst consensus estimate of $780.629 million [1] Financial Guidance - The company lowered its FY2025 adjusted EPS guidance from $4.40-$4.55 to $3.50-$3.60, while raising its sales guidance from $3.125 billion-$3.200 billion to $3.150 billion-$3.200 billion [2] - The CEO highlighted over 20% revenue growth from PALYNZIQ and VOXZOGO as key contributors to the business units [2] Stock Performance - Following the earnings announcement, BioMarin Pharmaceutical shares gained 4.3%, reaching $54.95 [3] - Analysts adjusted their price targets for the stock after the earnings report [3] Analyst Ratings - Morgan Stanley maintained an Overweight rating but lowered the price target from $104 to $98 [5] - HC Wainwright & Co. maintained a Neutral rating and cut the price target from $60 to $55 [5] - Barclays also maintained an Overweight rating, lowering the price target from $86 to $80 [5]